Dupilumab-associated cutaneous adverse events among adult patients with atopic dermatitis: A retrospective study

Dupilumab, a monoclonal antibody inhibiting interleukin (IL) 4 and IL- 13, is approved for the treatment of moderate to severe atopic dermatitis (AD) in children aged >= 6 years, adolescents, and adults. Both clinical trials and real- life data demonstrate its efficacy and safety. However, some cutaneous adverse events (cAEs) have been observed during real- world experiences. The authors' aim was to analyze the spectrum of cAEs in patients receiving dupilumab for the treatment of AD in a real- world setting. A retrospective review of electronic medical records was conducted for 916 patients (475 males and 541 females; mean age, 50.23 +/- 19.66 years [range, 18- 91 years]) who had received dupilumab for a minimum of 1 month for the treatment of AD from December 2018 to November 2022 at the Department of Dermatology of University Federico II of Naples (Italy). The mean duration of dupilumab treatment was 27.31 +/- 21.26 months. A total of 148 of 916 (16.15%) (90 males; mean age, 50.91 +/- 15.34 years) patients reported other cAEs apart of AD flare; namely, facial redness (82 of 916; 8.95%), psoriasis (39 of 916; 4.25%), alope- cia areata (11 of 916; 1.2%), skin peeling (11 of 916; 1.2%), parapsoriasis (three of 916; 0.32%), and vitiligo (two of 916; 0.21%). Thirty- one of 916 (3.38%) patients discontinued dupilumab because of cAEs (18 of 916; 1.96%) for facial redness, 10 of 916 (1.09%) for psoriasis, and three of 916 (0.32%) for parapsoriasis. In our population, most of the cAEs were mild and did not require discontinuation of dupilumab. These findings would enable dermatologists understand the cutaneous side effects of dupilumab better, resulting in improved treatment plan decisions in clinical practice.